CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Grant or award Chief Scientific Officer acquired 1,117,035 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award President and CEO acquired 1,264,587 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 7,899,572 shares (grant or award)
- 4 Open-market buy 10% owner bought 621.75 shares at $22.07 ($13,723)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Grant or award Former 10% owner acquired 1,152,460 shares (grant or award)
- 4 Open-market buy 10% owner bought 31,759 shares at an average $5.15 ($163,498)
- 4 Open-market sale CFO & COO sold 9,856 shares at $4.67 ($46,028)
- 4 Open-market sale Chief Executive Officer sold 32,861 shares at $4.66 ($153,132)
- 425 Deal Prospectus/Communication re Business Combination
- 8-K Event Shareholder rights changed · Executive or director change · Bylaws or fiscal year change · Shareholder vote results · Other events
- 3 Insider Initial Statement of Ownership
Page 29 of 40 · 798 filings